Phillip brings more than 20 years of leadership expertise in finance, mergers and acquisitions and operations focused in the pharmaceutical and healthcare industries. He has held leadership roles overseeing strategic transactions, financing management and accounting operations, controls and reporting processes for growing life sciences companies. Phillip has served as a member of AVROBIO’s board of directors and audit committee chairman since June 2018. He also serves on the board of directors and as the chairman of the audit committee of Taysha Gene Therapies, a gene therapy company.

Phillip is currently Senior Vice President and Chief Financial Officer of Jaguar Gene Therapy, LLC., an early-stage gene therapy company, and has served in such roles since February 2020. Previously, Phillip served as Chief Financial Officer and Senior Vice President of Assertio Therapeutics, Inc., a pharmaceutical company, from July 2018 to November 2018. Prior to that, he served as Senior Vice President and Chief Financial Officer of AveXis, Inc., a gene therapy company, from October 2017 to June 2018 and as Vice President, Corporate Controller from September 2016 to October 2017. Prior to joining AveXis, Phillip served as Chief Financial Officer of RestorGenex Corporation from 2014 until its merger with Diffusion Pharmaceuticals LLC, a pharmaceutical company, in January 2016, and served as the merged company’s consultant Chief Financial Officer until September 2016. Phillip earned a BS in accountancy from the University of Illinois Champaign-Urbana College of Business and is a Certified Public Accountant.